Dear Colleagues, Friends and Patients,

 

The Challenge

Over 266 million people suffer from degenerative spine disease each year. As people live longer, more active lives, their risk of disc degeneration and back pain rises, often leading to surgery. Traditional spinal fusion limits natural movement, fueling a revision epidemic with complications and costly readmissions—each surgery averaging over $25K USD. Many patients seek temporary relief from interventional pain management (IPM) physicians, relying on opioids or spinal cord stimulators—treatments that don’t address the root cause. The need for lasting solutions has never been greater.

 

Shaping the Future of Spine Technologies

We are not your typical healthtech private equity firm. Since our founder filed his first patent in 2000, we’ve been singularly focused on transforming spine surgery. For over 20 years, we’ve built, acquired, and commercialized breakthrough spine technologies, starting with the MANTIS percutaneous pedicle screw system—later acquired by Stryker. Today, we lead the field with AxioMed, the only viscoelastic total disc replacement that restores natural motion, and NANISX, the top outpatient platform for Less Exposure Spine Surgery (LESS™).

​

What Makes Us Unique?

We 100% own our portfolio companies and build for long-term value. We are physician-led, engineering-driven, and focused on innovation—not just financial returns. While large spine companies continue to rely on outdated fusion techniques with screws and cages, many—Synthes, Zimmer-Biomet, NuVasive, K2M, and Stryker—have been acquired, revealing gaps in innovation and waning confidence in the traditional spine market. We see these gaps as opportunities.

​

Why Bet on Us?

Led by Harvard-trained orthopedic spine surgeon and former Accenture Management Consultant Kingsley R. Chin, MD, MBA, we uniquely blend clinical expertise with engineering to develop 10x best-in-class solutions. Guided by our LESS™ philosophy—Restore Function, Early Intervention, Preserve Anatomy (REP)—we are pushing spine surgery forward into ambulatory surgery centers (ASCs), expanding patient access, reducing costs, and improving outcomes worldwide. By investing in us, you’re not just betting on the future of spine surgery—you’re betting on a proven model of innovation, ownership, and long-term growth in a market ripe for our 10x innovations..

 

Exclusive Investment Opportunity

For the first time, we invite investors into KIC Ventures as we scale toward a $5 billion valuation. We’re raising $15 million in our Series A to:

• Accelerate portfolio growth and market expansion

• 10x advance our technologies and invest in randomized controlled clinical studies

 

Maximizing Investor Returns

Our portfolio is built for acquisitions, IPOs, and strategic partnerships, ensuring strong investor returns through market consolidation and public offerings. Over 28 investors have contributed $4 million—an average of $142,000 per investor. Our goal to grow from $300 million to $5 billion within five years. Our strategy is clear: own cutting-edge spine technologies, scale adoption, and drive market leadership.

 

Secure your position now. Call Aditya Humad (267-342-3968) or visit www.KICVentures.com.

 

With gratitude,

The Executive Council | KIC Ventures